Atrial Fibrillation
Tuesday, February 26th, 2013
U.S. Food and Drug Administration: February 15, 2013 Public Comment You may submit written comments and suggestions at any time for Agency consideration to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, (HFA-305), Rockville, MD, 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the […]
Atrial Fibrillation
Tuesday, February 26th, 2013
PMJ.BMJ: February 12, 2013 Abstract Atrial fibrillation, the commonest cardiac arrhythmia, predisposes to thrombus formation and consequently increases risk of ischaemic stroke. Recent years have seen approval of a number of novel oral anticoagulants. Nevertheless, warfarin and aspirin remain the mainstays of therapy. It is widely appreciated that both these agents increase the likelihood of bleeding: […]
Atrial Fibrillation
Friday, February 22nd, 2013
JACC: February 19, 2013 Objectives This study sought to investigate differences in outcome between patients treated with successful strict, failed strict, and lenient rate control. Background The RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) study showed no difference in outcome between lenient and strict rate control in patients with permanent atrial fibrillation (AF). However, in the […]
Atrial Fibrillation
Friday, February 22nd, 2013
CIRCEP: February 12, 2013 Background-Prevalent atrial fibrillation (AF) is associated a higher sudden cardiac death (SCD) rate in some populations and incident AF predicts increased mortality risk in the general population and after myocardial infarction. However, the relationship of SCD to new-onset AF is unclear. Read more
Atrial Fibrillation
Friday, February 22nd, 2013
CIREP: February 7, 2013 Background-The foundation for successful arrhythmia ablation is the mapping of electrical propagation to identify underlying mechanisms. In atrial fibrillation (AF), however, mapping is difficult so that ablation has often targeted electrogram features, with mixed results. We hypothesized that wide-field of view (panoramic) mapping of both atria would identify causal mechanisms for AF […]
Atrial Fibrillation
Friday, February 8th, 2013
EHJ: February 5, 2013 Assessment of atrial fibrillation (AF)-associated stroke risk is at present mainly based on clinical risk scores such as CHADS2 and CHA2DS2-VASc, although these scores provide only modest discrimination of risk for individual patients. Biomarkers derived from the blood may help refine risk assessment in AF for stroke outcomes and for mortality. Recent […]
Atrial Fibrillation
Friday, February 8th, 2013
JACC: February 2013 Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Objectives The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care. Background Rivaroxaban is noninferior to warfarin for […]
Atrial Fibrillation
Friday, February 8th, 2013
JACC: February 2013 Objectives The purpose of this study was to analyze the effect of beta blockade on outcome in patients with heart failure (HF) and atrial fibrillation (AF). Background Beta-blockers are widely used in patients with HF and AF. Recommendation in current HF guidelines, however, is based on populations in which the most patients had sinus rhythm. […]
Atrial Fibrillation
Friday, February 8th, 2013
Nature: January 31, 2013 Encounters that set the heart aflutter are celebrated in love songs and romance literature. But that fluttery feeling can also be the first sign of a dangerous episode of atrial fibrillation (AF), the most common form of irregular heartbeat. And while the symptoms might be mild, or even unnoticeable, AF is a […]
Atrial Fibrillation
Friday, February 8th, 2013
Kardiologiapolska: 1/22/13 Background: Atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) is generally associated with deterioration of the clinical status, functional capacity, and quality of life. It is also an independent risk factor for stroke and death. Studies evaluating the effectiveness of AF ablation in this cohort are relatively scant, have included relatively few patients, and […]
